Insights into pathophysiology of punding reveal possible treatment strategies

Molecular Psychiatry

Volumn 15, Issue 6, 2010, Pages 560-573

  Fasano, A ^a   Petrovic, I ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Addiction; Cocaine; Dopamine; Impulse control disorders; Parkinson's disease; Punding

Indexed keywords

AMANTADINE; AMFEBUTAMONE; AMPHETAMINE; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CLOMIPRAMINE; COCAINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; PAROXETINE; PERGOLIDE; PRAMIPEXOLE; QUETIAPINE; ROPINIROLE; SELEGILINE; SERTRALINE; THREO 3,4 DIHYDROXYPHENYLSERINE; TOLCAPONE; TRAZODONE;

ADDICTION; CENTRAL NERVOUS SYSTEM DISEASE; DISEASE ASSOCIATION; DOPAMINE DYSREGULATION SYNDROME; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSKINESIA; HUMAN; HYPERSEXUALITY; IMPULSE CONTROL DISORDER; OBSESSIVE COMPULSIVE DISORDER; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; PUNDING; REVIEW; STEREOTYPY; SUBSTITUTION THERAPY;

AMPHETAMINE; BEHAVIOR, ADDICTIVE; CLINICAL PROTOCOLS; COCAINE; CORPUS STRIATUM; DOPAMINE AGONISTS; HUMANS; MODELS, BIOLOGICAL; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; STEREOTYPED BEHAVIOR; STEREOTYPIC MOVEMENT DISORDER;

EID: 77952870423     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2009.95     Document Type: Review

References (99)

1. Rylander G. Psychoses and the punding and choreiform syndromes in addiction to central stimulant drugs. Psychiatr Neurol Neurochir 1972; 75: 203-212.
2. Schiorring E. Psychopathology induced by 'speed drugs'. Pharmacol Biochem Behav 1981; 14(Suppl 1): 109-122.
3. Evans AH, Katzenschlager R, Paviour D, O'Sullivan JD, Appel S, Lawrence AD et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004; 19: 397-405.
4. Voon V. Repetition repetition, and repetition: compulsive and punding behaviors in Parkinson's disease. Mov Disord 2004; 19: 367-370.
5. Friedman JH. Punding on levodopa. Biol Psychiatry 1994; 36: 350-351.
6. Gallagher DA, O'Sullivan SS, Evans AH, Lees AJ, Schrag A. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord 2007; 22: 1757-1763.
7. Shapiro MA, Chang YL, Munson SK, Okun MS, Fernandez HH. Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases. Parkinsonism Relat Disord 2006; 12: 392-395.
8. Pontone G, Williams JR, Bassett SS, Marsh L. Clinical features associated with impulse control disorders in Parkinson disease. Neurology 2006; 67: 1258-1261.
9. Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 2006; 21: 524-529.
10. Voon V, Potenza MN, Thomsen T. Medication-related impulse control and repetitive behaviors in Parkinson's disease. Curr Opin Neurol 2007; 20: 484-492. (Pubitemid 47051998)
11. Serrano-Duenas M. Chronic dopamimetic drug addiction and pathologic gambling in patients with Parkinson's disease\presentation of four cases. Ger J Psychiatry 2002; 5: 62-67.
12. Grosset KA, Grosset DG. Proposed dose equivalence for rapid switching between dopamine agonists in Parkinson's disease. Clin Ther 2006; 28: 1063-1064; author reply 1064.
13. Brady KT, Lydiard RB, Malcolm R, Ballenger JC. Cocaine-induced psychosis. J Clin Psychiatry 1991; 52: 509-512.
14. Fasano A, Barra A, Nicosia P, Rinaldi F, Bria P, Bentivoglio AR et al. Cocaine addiction: from habits to stereotypical-repetitive behaviors and punding. Drug Alcohol Depend 2008; 96: 178-182.
15. Miyasaki JM, Al Hassan K, Lang AE, Voon V. Punding prevalence in Parkinson's disease. Mov Disord 2007; 22: 1179-1181.
16. Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH, Duda JE et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006; 63: 969-973.
17. American Psychiatric Association. Diagnostic and Statistical Manual of Psychiatry-Text Revision, 4th edn. Washington, DC, 2000.
18. Black KJ, Friedman JH. Repetitive and impulsive behaviors in treated Parkinson disease. Neurology 2006; 67: 1118-1119.
19. Stein DJ. Obsessive-compulsive disorder. Lancet 2002; 360: 397-405.
20. Fullana MA, Mataix-Cols D, Caspi A, Harrington H, Grisham JR, Moffitt TE et al. Obsessions and compulsions in the community: prevalence, interference, help-seeking, developmental stability, and co-occurring psychiatric conditions. Am J Psychiatry 2009; 166: 329-336.
21. Lawrence AJ, Blackwell AD, Barker RA, Spagnolo F, Clark L, Aitken MR et al. Predictors of punding in Parkinson's disease: results from a questionnaire survey. Mov Disord 2007; 22: 2339-2345.
22. Dell'Osso B, Altamura AC, Allen A, Marazziti D, Hollander E. Epidemiologic and clinical updates on impulse control disorders: a critical review. Eur Arch Psychiatry Clin Neurosci 2006; 256: 464-475.
23. Goodwin FK, Murphy DL, Brodie HK, Bunney Jr WE. Levodopa: alterations in behavior. Clin Pharmacol Ther 1971; 12: 383-396.
24. Bienvenu OJ, Samuels JF, Riddle MA, Hoehn-Saric R, Liang KY, Cullen BA et al. The relationship of obsessive-compulsive disorder to possible spectrum disorders: results from a family study. Biol Psychiatry 2000; 48: 287-293.
25. Lochner C, Hemmings SM, Kinnear CJ, Niehaus DJ, Nel DG, Corfield VA et al. Cluster analysis of obsessive-compulsive spectrum disorders in patients with obsessive-compulsive disorder: clinical and genetic correlates. Compr Psychiatry 2005; 46: 14-19.
26. Potenza MN, Voon V, Weintraub D. Drug Insight: impulse control disorders and dopamine therapies in Parkinson's disease. Nat Clin Pract Neurol 2007; 3: 664-672. (Pubitemid 350238058)
27. Voon V, Hassan K, Zurowski M, Duff-Canning S, de Souza M, Fox S et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 2006; 66: 1750-1752.
28. Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, Ahlskog JE. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005; 62: 1377-1381.
29. Szarfman A, Doraiswamy PM, Tonning JM, Levine JG. Association between pathologic gambling and parkinsonian therapy as detected in the Food and Drug Administration Adverse Event database. Arch Neurol 2006; 63: 299-300; author reply 300.
30. Fernandez HH, Friedman JH. Punding on L-dopa. Mov Disord 1999; 14: 836-838.
31. Chartoff EH, Marck BT, Matsumoto AM, Dorsa DM, Palmiter RD. Induction of stereotypy in dopamine-deficient mice requires striatal D1 receptor activation. Proc Natl Acad Sci USA 2001; 98: 10451-10456.
32. Silveira-Moriyama L, Evans AH, Katzenschlager R, Lees AJ. Punding and dyskinesias. Mov Disord 2006; 21: 2214-2217.
33. Fasano A, Elia AE, Soleti F, Guidubaldi A, Bentivoglio AR. Punding and computer addiction in Parkinson's disease. Mov Disord 2006; 21: 1217-1218.
34. McKeon A, Josephs KA, Klos KJ, Hecksel K, Bower JH, Michael Bostwick J et al. Unusual compulsive behaviors primarily related to dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 2007; 13: 516-519.
35. Miwa H, Morita S, Nakanishi I, Kondo T. Stereotyped behaviors or punding after quetiapine administration in Parkinson's disease. Parkinsonism Relat Disord 2004; 10: 177-180.
36. Erberk-Ozen N. Manic symptoms probably associated with short-term low-dose quetiapine use. Adv Ther 2008; 25: 53-58.
37. Evans AH, Stegeman JR. Punding in patients on dopamine agonists for restless leg syndrome. Mov Disord 2008; 24: 140-141.
38. Fan CC, Lin SK, Huang MC. Disulfiram-induced punding. J Clin Psychopharmacol 2008; 28: 473-474.
39. Bourdelat-Parks BN, Anderson GM, Donaldson ZR, Weiss JM, Bonsall RW, Emery MS et al. Effects of dopamine beta-hydroxylase genotype and disulfiram inhibition on catecholamine homeostasis in mice. Psychopharmacology (Berl) 2005; 183: 72-80.
40. Ikemoto S, Panksepp J. The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking. Brain Res Brain Res Rev 1999; 31: 6-41.
41. Wise RA, Rompre PP. Brain dopamine and reward. Annu Rev Psychol 1989; 40: 191-225.
42. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science 1997; 275: 1593-1599.
43. Jones SR, Garris PA, Wightman RM. Different effects of cocaine and nomifensine on dopamine uptake in the caudate-putamen and nucleus accumbens. J Pharmacol Exp Ther 1995; 274: 396-403.
44. Venton BJ, Seipel AT, Phillips PE, Wetsel WC, Gitler D, Greengard P et al. Cocaine increases dopamine release by mobilization of a synapsin-dependent reserve pool. J Neurosci 2006; 26: 3206-3209.
45. Robbins TW, Mittleman G, O'Brien CP, Winn P. The neuropsycho-logical significance of stereotypy induced by stimulant drugs. In: Cooper SJ, Dourish CT (eds). Neurobiology of Stereotyped Behaviour. Oxford: Claredon Press, 1990. pp 25-63.
46. Toates F. The interaction of cognitive and stimulus-response processes in the control of behaviour. Neurosci Biobehav Rev 1998; 22: 59-83.
47. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000; 68: 423-428.
48. Pezzella FR, Colosimo C, Vanacore N, Di Rezze S, Chianese M, Fabbrini G et al. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord 2005; 20: 77-81.
49. Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol 2003; 2: 595-604.
50. Katajamaki J, Honkanen A, Piepponen TP, Linden IB, Zharkovsky A, Ahtee L. Conditioned place preference induced by a combination of L-dopa and a COMT inhibitor, entacapone, in rats. Pharmacol Biochem Behav 1998; 60: 23-26.
51. van der Kooy D, Swerdlow NR, Koob GF. Paradoxical reinforcing properties of apomorphine: effects of nucleus accumbens and area postrema lesions. Brain Res 1983; 259: 111-118.
52. Papp M. Different effects of short-and long-term treatment with imipramine on the apomorphine-and food-induced place preference conditioning in rats. Pharmacol Biochem Behav 1988; 30: 889-893.
53. Hoffman DC, Dickson PR, Beninger RJ. The dopamine D2 receptor agonists, quinpirole and bromocriptine produce conditioned place preferences. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12: 315-322.
54. Zito KA, Vickers G, Roberts DC. Disruption of cocaine and heroin self-administration following kainic acid lesions of the nucleus accumbens. Pharmacol Biochem Behav 1985; 23: 1029-1036.
55. Nocjar C, Panksepp J. Chronic intermittent amphetamine pretreat-ment enhances future appetitive behavior for drug-and natural-reward: interaction with environmental variables. Behav Brain Res 2002; 128: 189-203.
56. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord 2007; 22: 1379-1389; quiz 1523.
57. Aubert I, Guigoni C, Hakansson K, Li Q, Dovero S, Barthe N et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 2005; 57: 17-26.
58. Graybiel AM, Canales JJ, Capper-Loup C. Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis. Trends Neurosci 2000; 23: S71-S77.
59. Randrup A, Munkvad I. Stereotyped activities produced by amphetamine in several animal species and man. Psychopharma-cologia 1967; 11: 300-310.
60. Kamath S, Bajaj N. Crack dancing in the United Kingdom: apropos a video case presentation. Mov Disord 2007; 22: 1190-1191.
61. Pierce RC, Kalivas PW. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Brain Res Rev 1997; 25: 192-216.
62. Clark D, White FJ. D1 dopamine receptor-the search for a function: a critical evaluation of the D1/D2 dopamine receptor classification and its functional implications. Synapse 1987; 1: 347-388.
63. Ridley RM. The psychology of perserverative and stereotyped behaviour. Prog Neurobiol 1994; 44: 221-231.
64. Robinson TE, Becker JB. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 1986; 396: 157-198.
65. Robbins TW, Everitt BJ. Functional studies of the central catecholamines. Int Rev Neurobiol 1982; 23: 303-365.
66. Gerfen CR. The neostriatal mosaic: compartmentalization of corticostriatal input and striatonigral output systems. Nature 1984; 311: 461-464.
67. Saka E, Goodrich C, Harlan P, Madras BK, Graybiel AM. Repetitive behaviors in monkeys are linked to specific striatal activation patterns. J Neurosci 2004; 24: 7557-7565.
68. Kashihara K, Imamura T. Amantadine may reverse punding in Parkinson's disease\observation in a patient. Mov Disord 2008; 23: 129-130.
69. Everitt BJ, Dickinson A, Robbins TW. The neuropsychological basis of addictive behaviour. Brain Res Brain Res Rev 2001; 36: 129-138.
70. Vanderschuren LJ, Di Ciano P, Everitt BJ. Involvement of the dorsal striatum in cue-controlled cocaine seeking. J Neurosci 2005; 25: 8665-8670.
71. Graybiel AM, Aosaki T, Flaherty AW, Kimura M. The basal ganglia and adaptive motor control. Science 1994; 265: 1826-1831.
72. Volkow ND, Wang GJ, Telang F, Fowler JS, Logan J, Childress AR et al. Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. J Neurosci 2006; 26: 6583-6588.
73. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005; 162: 1403-1413.
74. Di Chiara G, Bassareo V. Reward system and addiction: what dopamine does and doesn't do. Curr Opin Pharmacol 2007; 7: 69-76.
75. Whishaw IQ, Fiorino D, Mittleman G, Castaneda E. Do forebrain structures compete for behavioral expression? Evidence from amphetamine-induced behavior, microdialysis, and caudate-ac-cumbens lesions in medial frontal cortex damaged rats. Brain Res 1992; 576: 1-11.
76. Jentsch JD, Taylor JR. Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacology (Berl) 1999; 146: 373-390.
77. Volle E, Beato R, Levy R, Dubois B. Forced collectionism after orbitofrontal damage. Neurology 2002; 58: 488-490.
78. Mink JW. The basal ganglia: focused selection and inhibition of competing motor programs. Prog Neurobiol 1996; 50: 381-425.
79. Barnes J, Boubert L. Executive functions are impaired in patients with Parkinson's disease with visual hallucinations. J Neurol Neurosurg Psychiatry 2008; 79: 190-192.
80. Matochik JA, London ED, Eldreth DA, Cadet JL, Bolla KI. Frontal cortical tissue composition in abstinent cocaine abusers: a magnetic resonance imaging study. Neuroimage 2003; 19: 1095-1102.
81. Tucker KA, Potenza MN, Beauvais JE, Browndyke JN, Gottschalk PC, Kosten TR. Perfusion abnormalities and decision making in cocaine dependence. Biol Psychiatry 2004; 56: 527-530.
82. Braak H, Bohl JR, Muller CM, Rub U, de Vos RA, Del Tredici K. Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord 2006; 21: 2042-2051.
83. Anderson SW, Damasio H, Damasio AR. A neural basis for collecting behaviour in humans. Brain 2005; 128: 201-212.
84. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord 2005; 20(Suppl 11): S11-S16.
85. Shin HS. Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Drug Metab Dispos 1997; 25: 657-662.
86. Levin FR, Evans SM, Coomaraswammy S, Collins ED, Regent N, Kleber HD. Flupenthixol treatment for cocaine abusers with schizophrenia: a pilot study. Am J Drug Alcohol Abuse 1998; 24: 343-360.
87. Grant JE, Kim SW. Medication management of pathological gambling. Minn Med 2006; 89: 44-48.
88. Nguyen FN, Pauly RR, Okun MS, Fernandez HH. Punding as a complication of brain stem stroke?: report of a case. Stroke 2007; 38: 1390-1392.
89. Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75: 141-143.
90. Durif F, Debilly B, Galitzky M, Morand D, Viallet F, Borg M et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 2004; 62: 381-388.
91. Rodrigues JP, Walters SE, Watson P, Stell R, Mastaglia FL. Globus pallidus stimulation in advanced Parkinson's disease. J Clin Neurosci 2007; 14: 208-215.
92. Shahed J, Poysky J, Kenney C, Simpson R, Jankovic J. GPI deep brain stimulation for Tourette syndrome improves tics and psychiatric comorbidities. Neurology 2007; 68: 159-160.
93. Meseguer Gancedo E, Garcia Ruiz P. Punding in Parkinson's disease. Neurologia 2002; 17: 228.
94. Kumar S. Punding in Parkinson's disease related to high-dose levodopa therapy. Neurol India 2005; 53: 362.
95. Miwa H, Kondo T. Increased writing activity in Parkinson's disease: a punding-like behavior? Parkinsonism Relat Disord 2005; 11: 323-325.
96. Kummer A, Maia DP, Salgado JV, Cardoso FE, Teixeira AL. Dopamine dysregulation syndrome in Parkinson's disease: case report. Arq Neuropsiquiatr 2006; 64: 1019-1022.
97. Bonvin C, Horvath J, Christe B, Landis T, Burkhard PR. Compulsive singing: another aspect of punding in Parkinson's disease. Ann Neurol 2007; 62: 525-528.
98. O'Sullivan SS, Evans AH, Lees AJ. Punding in Parkinson's disease. Pract Neurol 2007; 7: 397-399.
99. Jenner P. Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease. Curr Opin Neurol 2003; 16(Suppl 1): S3-S7.